Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

1.

Systematic adjudication of myocardial infarction end-points in an international clinical trial.

Mahaffey KW, Harrington RA, Akkerhuis M, Kleiman NS, Berdan LG, Crenshaw BS, Tardiff BE, Granger CB, DeJong I, Bhapkar M, Widimsky P, Corbalon R, Lee KL, Deckers JW, Simoons ML, Topol EJ, Califf RM; For the PURSUIT Investigators.

Curr Control Trials Cardiovasc Med. 2001 Jul 17;2(4):180-186.

PMID:
11806793
[PubMed - as supplied by publisher]
Free PMC Article
2.

Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study.

Mahaffey KW, Harrington RA, Akkerhuis M, Kleiman NS, Berdan LG, Crenshaw BS, Tardiff BE, Granger CB, DeJong I, Bhapkar M, Widimsky P, Corbalon R, Lee KL, Deckers JW, Simoons ML, Topol EJ, Califf RM; For the PURSUIT Investigators.

Curr Control Trials Cardiovasc Med. 2001 Jul 17;2(4):187-194.

PMID:
11806794
[PubMed - as supplied by publisher]
Free PMC Article
3.

Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial.

Mahaffey KW, Roe MT, Dyke CK, Newby LK, Kleiman NS, Connolly P, Berdan LG, Sparapani R, Lee KL, Armstrong PW, Topol EJ, Califf RM, Harrington RA.

Am Heart J. 2002 Feb;143(2):242-8.

PMID:
11835026
[PubMed - indexed for MEDLINE]
4.

Diagnostic criteria and adjudication process both determine published event-rates: the ACTION trial experience.

Kirwan BA, Lubsen J, de Brouwer S, Danchin N, Battler A, Bayes de Luna A, Dunselman PH, Glasser S, Koudstaal PJ, Sutton G, van Dalen FJ, Poole-Wilson PA; ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators.

Contemp Clin Trials. 2007 Nov;28(6):720-9. Epub 2007 Apr 19.

PMID:
17509947
[PubMed - indexed for MEDLINE]
5.

Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes.

Mahaffey KW, Roe MT, Kilaru R, French JK, Alexander JH, Berdan LG, Van De Werf F, Simoons ML, Weaver WD, White HD, Lincoff AM, Kleiman NS, Topol EJ, Harrington RA.

Am J Cardiol. 2005 Jun 15;95(12):1404-8.

PMID:
15950560
[PubMed - indexed for MEDLINE]
6.

Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.

Granada JF, Kleiman NS.

Am J Cardiovasc Drugs. 2004;4(1):31-41. Review.

PMID:
14967064
[PubMed - indexed for MEDLINE]
7.

Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (β-Blocker Evaluation of Survival Trial [BEST]).

Carson P, Fiuzat M, O'Connor C, Anand I, Plehn J, Lindenfeld JA, Silver M, White M, Miller A, Davis G, Robertson AD, Bristow M, Gottlieb S.

Am Heart J. 2010 Oct;160(4):649-54. doi: 10.1016/j.ahj.2010.07.004.

PMID:
20934558
[PubMed - indexed for MEDLINE]
8.

Clinical endpoint adjudication in a contemporary all-comers coronary stent investigation: methodology and external validation.

Vranckx P, McFadden E, Cutlip DE, Mehran R, Swart M, Kint PP, Zijlstra F, Silber S, Windecker S, Serruys PW.

Contemp Clin Trials. 2013 Jan;34(1):53-9. doi: 10.1016/j.cct.2012.08.012. Epub 2012 Sep 10.

PMID:
22975439
[PubMed - indexed for MEDLINE]
9.

Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial.

Labinaz M, Kaul P, Harrington RA, Chang WC, Kleiman NS, Simoons ML, Boersma E, Akkerhuis KM, Califf RM, Armstrong PW; PURSUIT investigators.

Can J Cardiol. 2004 Jun;20(8):773-8.

PMID:
15229770
[PubMed - indexed for MEDLINE]
10.

The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points.

Näslund U, Grip L, Fischer-Hansen J, Gundersen T, Lehto S, Wallentin L.

Eur Heart J. 1999 May;20(10):771-7.

PMID:
10329069
[PubMed - indexed for MEDLINE]
Free Article
11.

The role of eptifibatide in patients undergoing percutaneous coronary intervention.

Zeymer U.

Expert Opin Pharmacother. 2007 Jun;8(8):1147-54. Review.

PMID:
17516878
[PubMed - indexed for MEDLINE]
12.

Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.

Puma JA, Banko LT, Pieper KS, Sacchi TJ, O'Shea JC, Dery JP, Tcheng JE.

J Am Coll Cardiol. 2006 Feb 21;47(4):715-8. Epub 2006 Jan 26.

PMID:
16487833
[PubMed - indexed for MEDLINE]
Free Article
13.

Do we need to adjudicate major clinical events?

Granger CB, Vogel V, Cummings SR, Held P, Fiedorek F, Lawrence M, Neal B, Reidies H, Santarelli L, Schroyer R, Stockbridge NL, Feng Zhao.

Clin Trials. 2008;5(1):56-60. doi: 10.1177/1740774507087972. Review.

PMID:
18283081
[PubMed - indexed for MEDLINE]
14.

Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.

Curran MP, Keating GM.

Drugs. 2005;65(14):2009-35. Review.

PMID:
16162023
[PubMed - indexed for MEDLINE]
15.
16.

Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials.

Mehta RH, Greenbaum AB, Lokhnygina Y, Newby LK, Van De Werf F, Armstrong PW, Pieper KS, Califf RM, Granger CB, Harrington RA.

J Interv Cardiol. 2007 Oct;20(5):299-306.

PMID:
17880325
[PubMed - indexed for MEDLINE]
17.

Comparing classifications of death in the Mode Selection Trial: agreement and disagreement among site investigators and a clinical events committee.

Petersen JL, Haque G, Hellkamp AS, Flaker GC, Mark Estes NA 3rd, Marchlinski FE, McAnulty JH, Greenspon AJ, Marinchak RA, Lee KL, Lamas GA, Mahaffey KW; MOST Clinical Events Committee.

Contemp Clin Trials. 2006 Jun;27(3):260-8. Epub 2006 Mar 29.

PMID:
16574497
[PubMed - indexed for MEDLINE]
18.

Cost effectiveness in Canada of eptifibatide treatment for acute coronary syndrome patients using PURSUIT subgroup analysis.

Brown R, Armstrong P; Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.

Can J Cardiol. 2003 Feb;19(2):161-6.

PMID:
12601441
[PubMed - indexed for MEDLINE]
19.

Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa.

O'Shea JC, Tcheng JE.

Expert Opin Pharmacother. 2002 Aug;3(8):1199-210. Review.

PMID:
12150697
[PubMed - indexed for MEDLINE]
20.

Spotlight on eptifibatide in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.

Curran MP, Keating GM.

BioDrugs. 2006;20(1):63-5. Review.

PMID:
16573353
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk